How Much of GLP-1 Weight Loss Is Muscle?
Across trials, lean mass accounts for anywhere from under 15% to 60% of weight lost on GLP-1 therapies. That spread is the story.
It depends enormously on the study, and that is the finding. A 2024 review in Diabetes, Obesity and Metabolism reports that lean mass accounted for 40% to 60% of total weight lost in some trials of GLP-1 receptor agonist and dual-agonist therapies, and roughly 15% or less in others. Same drug class, four-fold difference in outcome.
How much lean mass do people lose on GLP-1 medications?
The honest answer is a range, not a number. Neeland and colleagues reviewed the trial evidence and found the reported lean mass share of total weight lost varies from under 15% to 60% across studies.
Their review covers two related drug classes, often discussed as one but not pharmacologically identical: GLP-1 receptor agonists such as semaglutide, and dual agonists such as tirzepatide, which acts on both the GLP-1 and GIP receptors.
A 2026 systematic review in the International Journal of Obesity pooled seven randomised controlled trials covering 821 patients with obesity. It found two things at once. Lean mass as a proportion of total body weight improved by 1.81% (95% CI 1.1 to 2.52). Absolute lean mass fell by 1.74 kg (95% CI -3.04 to -0.45).
Both can be true at once. Fat was lost faster than lean tissue, so the ratio moved favourably even as the absolute quantity dropped. Heterogeneity on those absolute estimates was extremely high (I² = 98%), meaning the trials disagree sharply and the pooled figure is the centre of a wide spread, not a reliable expectation.
Why does the same drug produce such different body composition results?
Because body composition responds to more than the drug. The trials in these reviews differ in participant age, baseline muscle mass, protein intake, resistance training, and the rate of weight loss itself, none of which are held constant across studies.
That is what makes the scale a weak instrument here. Two people can lose an identical number of kilograms over an identical period and end up with meaningfully different amounts of skeletal muscle, and neither would know from the number under their feet. Distinguishing the two requires measuring composition, not mass: DXA, bioimpedance, or serial strength and functional measures over time.
The bottom line
- Across trials, lean mass has accounted for anywhere from under 15% to 60% of total weight lost on GLP-1 therapies.
- A 2026 meta-analysis of seven RCTs (821 patients) found lean mass rose as a proportion of body weight by 1.81% while falling by 1.74 kg in absolute terms.
- Heterogeneity across those trials was very high (I² = 98%), so the range matters more than the average.
- Total weight cannot distinguish between these outcomes. Body composition measurement can.
Frequently asked questions
- Does semaglutide or tirzepatide cause muscle loss?
- Some lean tissue is lost during weight loss on semaglutide and tirzepatide, though fat is generally lost faster, so body composition ratios tend to improve. Trial estimates of the lean mass share of total weight lost range from under 15% to 60%, a spread wide enough that population averages say little about any individual.
- How is lean mass actually measured?
- Most trials use DXA (dual-energy X-ray absorptiometry), which separates fat, lean soft tissue and bone. Newer studies use MRI to quantify muscle volume and fat infiltration directly. Bathroom scales that estimate body fat by bioimpedance are far less precise, though useful for tracking direction over time.
Sources
- Neeland IJ, Linge J, Birkenfeld AL, 2024. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism 26(Suppl 4):16-27.
- Laverde LP, Muñoz-Velandia OM, Alfonso D, Gómez Medina AM, et al., 2026. Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials. International Journal of Obesity 50(8).